Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 5/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12650368 | 0.87 | BTK (0.37) | BTKCALCRLBRD4MAPTADORA2A | |
| SCHEMBL12602931 | 0.87 | BTK (0.37) | BTKCALCRLBRD4MAPTJAK2 | |
| SCHEMBL12650328 | 0.84 | BTK (0.36) | BTKCALCRLBRD4MAPTADORA2A | |
| SCHEMBL107567 | 0.83 | BTK (0.38) | BTKCALCRLBRD4MAPTADORA2A | |
| SCHEMBL104651 | 0.82 | HDAC1 (0.38) | BTKCALCRLMAPTADORA2AADORA2B | |
| SCHEMBL103354 | 0.80 | ADORA1 (0.38) | BTKCALCRLBRD4MAPTADORA2A | |
| SCHEMBL103863 | 0.78 | ROCK2 (0.42) | BTKCALCRLBRD4 | |
| SCHEMBL3656572 | 0.73 | BTK (0.34) | BTKCALCRLBRD4MAPTADORA2A | |
| SCHEMBL13894055 | 0.71 | ITK (0.36) | — | |
| SCHEMBL13893947 | 0.70 | GPR142 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | claimed |
| EP-2426109-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | disclosed |
| CN-101835755-B | Novel kinase inhibitors | HOFFMANN LA ROCHE | 2013-12-11 | — | — | CN | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| CN-101835755-A | Novel kinase inhibitors | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | BTK 1/4885CALCRL 1485/4885BRD4 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.